In conclusion, this study confirmed circulatory cytohesin 2, calumenin and S100A6 as biomarkers in Ssc patients and found associations between the serum levels of these biomarkers and clinical characteristics, especially with severe cutaneous involvement (necrosis and diffuse sclerosis). Here, S100A6 is linked to systemic sclerosis.